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Abstract
The extent of heterogeneity of driver gene mutations present in naturally occurring metastases is 
largely unknown, i.e. treatment-naïve metastatic disease. To address this issue, 60× whole genome 
sequencing of 26 metastases from 4 patients was carried out. We found that the identical driver 
gene mutations were present in every metastatic lesion of each patient studied. Passenger gene 
mutations not known or predicted to have functional consequences accounted for all intratumoral 
heterogeneity. Even with respect to these passenger gene mutations, the genetic similarity among 
the founding cells of metastases was markedly higher than that expected for any two cells 
randomly taken from a normal tissue. The uniformity of driver gene mutations among metastases 
in the same patient has critical, encouraging implications for the success of future targeted 
therapies in advanced stage disease.
The advent of next generation sequencing coupled with multi-region sampling has brought 
heterogeneity to the forefront of cancer genetics1,2. Remarkable examples of this 
phenomenon have been shown in carcinomas of the breast3, kidney4, lung5,6, prostate7–9, 
colon10, pancreas11,12, and melanoma13. Subclonal populations within a neoplasm are 
phylogenetically related and can be traced back to a single ancestral population based on 
their complement of somatic mutations14. Such heterogeneity has been extensively 
documented for more than 50 years, and is expected based on the imperfection of DNA 
replication: every time a normal cell or a cancer cell divides, ~3 new mutations appear15.
There are at least three types of intratumoral genetic heterogeneity: Type 1 – those mutations 
that distinguish one cell in a primary tumor from another cell of that same primary tumor; 
Type 2 - those that distinguish one cell in a metastatic lesion from another cell in that same 
metastatic lesion; and Type 3 - those within the same primary tumor that distinguish the cell 
that initiates one metastasis from the cell that initiates another distinct metastasis16,17. Each 
of these types of heterogeneity has distinct and important clinical implications. For example, 
Type 1 and 2 heterogeneities explain in part how primary tumors and metastatic lesions, 
respectively, develop resistance to therapies that are initially effective18–20. Type 3 
heterogeneity determines whether metastases within the same patient with advanced disease 
will respond to initial interventions. In the current age of targeted therapeutics, this type of 
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heterogeneity has become of paramount importance: unless nearly every metastatic lesion 
has the same driver gene mutation that the therapy targets, the therapy will fail. Finally, there 
also exists interpatient heterogeneity that helps explain why patients with the same 
histopathologic type of tumor respond so differently to the same drug regimen21.
Despite its importance, there have been few studies that have evaluated Type 3 heterogeneity 
through genome-wide sequencing. For example, we could find only four recent publications 
that have evaluated more than two metastases from any explicitly untreated patient11–13,22. 
Although several other studies have evaluated metastatic lesions after therapy, the genetic 
alterations in such lesions often reflect the mutagenic influences and strong selective 
pressures and bottlenecks associated with therapy rather than the natural course of disease. 
Other studies that evaluated somatic copy number alterations (SCNAs), either through 
karyotypes or other technologies, have been published but the changes evaluated can 
generally not be interpreted with respect to driver genes23,24.
In the current study, we evaluated Type 3 heterogeneity in Pancreatic Ductal 
Adenocarcinomas (PDACs). PDAC is notorious for presenting as metastatic disease at 
diagnosis and has a dismal five year survival rate (7%); it is projected to become the third 
most common cause of cancer death by the end of next year25.
RESULTS
Patient and sample cohort
We implemented strict clinical and technical criteria to identify the optimal patients for 
study from more than 150 autopsied patients for which tissues were available from a Rapid 
Medical Donation Program (Supplemental Table 1)26. First, we exclusively used samples 
from untreated patients for the reasons described above. Second, patients with unusual 
biological variants of PDAC were also excluded because they differ from the more common 
ductal adenocarcinomas in their pathogenesis, driver gene alterations27–29, and clinical 
outcomes30,31. Third, we required that all patients have Stage IV disease, that at least two 
metastases were available for study, and that the metastases available from each patient 
accurately represented their disease burden at autopsy (Supplemental Table 1).
Based on these criteria, we identified four patients for detailed evaluation. Histologic 
sections were prepared from snap frozen samples of the primary tumors and metastases from 
these four patients to estimate tumor cellularity and tissue quality. Samples with low 
neoplastic cellularity were excluded, as were any tissue samples with confluent necrosis that 
would yield low quality genomic DNA (gDNA) (Methods). The remaining samples were 
macrodissected to remove as much normal tissue as possible before purifying gDNA. A 
similar approach was previously described11, but in that study only a single metastasis from 
each patient was evaluated by genome-wide Sanger sequencing, precluding quantification of 
heterogeneity and limiting the ability to discern evolutionary relationships among metastatic 
lesions. In all, we identified 26 metastatic lesions suitable for study, as well as samples of 
the primary tumor and normal tissues, from these four patients (Supplemental Tables 2 and 
3).
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Genomic DNA from 39 samples (26 metastatic lesions, up to three distinct regions of each 
primary tumor, and normal tissues) were evaluated by 60× whole genome sequencing 
(WGS) using an Illumina Hi-Seq 2000 platform32 (Figure 1a, 1b). Importantly, all 
metastases were discrete tumors by both gross examination at autopsy and histologic review, 
ensuring that each metastasis represented an independent neoplasm at that location (Figure 
1c). The metastases were derived from diverse organs including the liver, lung, peritoneum 
and lymph nodes, all typical secondary sites of pancreatic cancer33. DNA from the normal 
tissues of each patient was used to facilitate identification of somatic variants.
Somatic and driver gene mutations identified
The raw data were filtered for mapping quality and aligned to the hg19 human reference 
genome, revealing an average coverage of 68× with 97.6% of bases covered at >10×. 
(Supplemental Table 4). As KRAS is mutated in PDACs at a high frequency, we used the 
mutant allele fraction (MAF) of KRAS as an independent metric of neoplastic cellularity of 
our samples. This is particularly important given the high non-neoplastic stromal content of 
many PDACs34.
It is well known that massively parallel sequencing yields many artifacts32,35. Moreover, 
varying estimates of tumor content across samples within an individual complicated 
identification of parsimony-informative mutations for inferring the genetic relationships 
among different lesions. We therefore employed filtering criteria to limit potential 
sequencing artifacts and enrich for true somatic mutations within this sequencing dataset 
(Methods), resulting in a list of 3811 unique variants among the samples. The vast majority 
of these mutations were shared among all samples from the same patient (Figure 2a and 
Supplementary Figure 1). Private (unique) somatic mutations within each primary tumor 
sample and different metastases were nonetheless identified as expected. KRAS mutations 
were identified in every sample of all four patients. Mutations in other driver genes, e.g., 
TP53, SMAD4, ARID1A, and ATM36,37, were also identified in all samples of each patient 
in which any lesion from that patient contained a mutation (Supplemental Table 5).
Homozygous deletions or amplifications that target critical driver genes are not detectable by 
sequencing of tumor samples that contain contaminating non-neoplastic cells. This is of 
particular importance for those tumor suppressor gene deletions in PDAC, in which 
homozygous deletion is a common mechanism of inactivation21. To address this issue, we 
first immunolabeled each sequenced tissue sample for the proteins encoded by CDKN2A, 
TP53 and SMAD4, all of which are frequently inactivated in PDACs. Loss of expression for 
CDKN2A was noted in the primary tumors of all four patients, suggesting that a 
homozygous deletion or epigenetic silencing was responsible for the inactivation of these 
tumor suppressor genes38. Importantly, every metastatic lesion of each of these four patients 
exhibited loss of expression of CDKN2A (Figure 2b). Similarly, loss of expression of TP53 
in Pam01 and Pam03 was identified in all samples from these two patients, which were the 
two not found to exhibit mutations detectable by WGS. Of interest, known homozygous 
deletions of CDKN2A and TP53 have previously been reported in a cell line derived from 
Pam01 (PA03C in36). Missense mutations identified in TP53 for Pam02 (p.L344P), in 
ARID1A for Pam02 (p.Y579X) and in SMAD4 for Pam04 (p.D351G) showed immune-
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labeling patterns concordant with the predicted effects of these mutations (Supplementary 
Figure 2), and these labeling patterns were also uniformly present in all samples of each 
studied patient.
In conjunction with the sequencing and immunohistochemistry results, we reviewed the 
predicted SCNAs in each sample to further assess genetic amplifications or deletions. We 
observed many common, partially shared or private copy number variants among the 
samples within each case, most of which encompassed large numbers (tens to thousands) of 
genes (Figure 2c, Supplementary Figures 3–7, Supplemental Table 6). In these regions, 
distinction between a evolutionarily selected low level copy number event versus stochastic 
aneuploidy is challenging23,24,39. However, some patterns emerged. We noted that the higher 
the fold of amplification, the fewer genes that were included in that amplicon. This led to 
identification of candidate somatic target genes with a reasonable level of certainty. 
Examples of such focal gains were GATA6 and MYC in Pam01 and KRAS in Pam02. These 
gains were present in every sample in each patient (Supplemental Table 7). Copy number 
losses of tumor suppressor genes such as ARID1A, CDKN2A, ROBO1, SMAD4, 
SMARCA2, or TP53 were also identified. Losses followed a similar trend, in that the fewer 
genes involved in the region of loss, the more likely it involved an undisputed PDAC driver 
gene, e.g., CDKN2A in Pam04 (Supplemental Table 7)21. In some instances, losses appeared 
to be heterogeneous across different samples from the same patient, for example SMAD4 in 
Pam01 and CDKN2A in Pam02. However, as discussed above, immunohistologic evaluation 
of these two genes showed complete concordance in all sequenced samples for each patient. 
In samples with relatively low levels of neoplastic cells, these data suggest that 
immunohistological analysis can add clarity to the interpretation of “negative” sequencing 
data, i.e., when homozygous losses are not easily identified.
We also identified putative structural variants for each case (Supplemental Tables 8–11, 
Supplementary Figure 8). These included 3516 break-ends (average 101 per sample), 2763 
inversions (average 79 per sample), 1291 tandem duplications (average 37 per sample), and 
48 insertions (average 2 per sample). Of these, a minor fraction involved known or candidate 
genes in PDAC, most of which were already identified by immunolabeling or copy number 
analysis. However, one liver metastasis from each of patients Pam02 and Pam03 exhibited 
several unique inversions, the significance of which is not clear (Supplementary Figure 8). 
Similarly, it is at present difficult to determine the importance, if any, of structural variations 
not adjacent to driver genes12,21,27.
Quantifying Type 3 heterogeneity
To address the extent of Type 3 heterogeneity in a quantitative fashion, we assessed the 
differences in single base substitutions among the founding cells of metastases with respect 
to a null model of genetic heterogeneity. The classical null model, genetic identity, assumes 
that all tumor cells exhibit exactly the same genetic mutations. However, as the tumors we 
evaluated are composed of exponentially growing populations of billions of cells, a null 
model of genetic identity seems unsuitable given the known imperfection of DNA 
replication. We therefore employed the expected genetic differences in normal tissues as an 
appropriate null model to assess genetic heterogeneity.
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To ensure that only the highest quality data were used for these analyses, we used a targeted 
sequencing approach based on custom-designed capture probes containing ~100 nt 
surrounding the 3811 variants of interest. Targeted sequencing was performed on the 
original 39 samples used for WGS plus four additional metastatic lesions from the same four 
patients. In total, we identified 614 bona fide mutations in the metastases through this 
targeted approach (Methods, Supplemental Tables 2, 3, and 12). This highly curated list of 
614 mutations included those in passenger genes as well as in the drivers of pancreatic 
cancer described above, with a median distinct depth of sequencing of 255× (Supplemental 
Table 4).
We investigated two measures of genetic heterogeneity: genetic distances (“divergence”)40 
and Jaccard similarity coefficients. Genetic distance is defined by the total number of non-
shared genetic variants present between two samples. The Jaccard similarity coefficient is 
defined as the ratio of shared variants over all variants (shared plus discordant) between two 
samples (Table 1 and Supplemental Table 13). For example, two metastatic lesions from the 
same patient sharing zero mutations would result in a Jaccard similarity coefficient of zero 
while two lesions with completely identical mutations would result in a coefficient of 1. The 
similarity coefficient is indifferent to the number of base pairs sequenced in the various 
samples, some of which differed considerably (Supplemental Table 4).
Because mutations present in founder cells of each metastasis are by definition present in all 
cells of the metastasis once the founder cells clonally expand, all mutations present in the 
founder cells can be detected by bulk sequencing. The total, measured heterogeneity among 
metastases thus reflects those of the individual founder cells (Type 3 heterogeneity) plus 
additional heterogeneity resulting from high frequency mutations subsequently acquired 
during the growth of the metastasis (Type 2 heterogeneity). The measured Jaccard similarity 
indices therefore represent an upper bound on Type 3 heterogeneity. In contrast, standard 
bulk sequencing of DNA from normal tissues is not appropriate for comparison, as this 
sequencing would not identify differences among individual cells41,42. Likewise, single cell 
sequencing is currently too error-prone to rely on the data from a single cell, and generally 
requires identification of the same mutation in more than one cell for accuracy14. Given 
these challenges, we employed an alternative approach in which the somatic evolution of 
most types of normal tissues was modeled. The models incorporated stochastic evolutionary 
processes with differing renewal patterns (Figure 3a; Supplementary Note). In the simplest 
case (Scenario 1), we modeled an organ that grows via a pure birth branching process to 
Ncell cells with no further cell divisions (mimicking neuronal cells, for example). For Ncell = 
1010, the expected Jaccard similarity coefficient was ~0.03 for two randomly chosen cells 
from the tissue. For a more complex case (Scenario 2), we derived the similarity coefficient 
for an organ with Ncrypt cells, where each cell founded a single geographically isolated 
compartment (such as an intestinal crypt) that continuously replenishes itself, with no 
mixing or replacement (mimicking intestinal epithelial cells). In this case, the coefficient 
was less than 0.04 in two randomly chosen cells from the tissue (assuming Ncrypt = 107 
cells). Finally, we considered a tissue with Nstem stem cells that not only continuously 
divides but also exhibits high replacement and mixing (mimicking hematopoietic cells; 
Scenario 3). For this final scenario, the Jaccard similarity coefficient was <0.2 for relevant 
time scales and cell population sizes (N >104 cells) and further diminished with the 
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population size of an organ. Thus, for two randomly chosen cells from healthy tissues of 
various renewal types, the expected similarity coefficients ranged from near zero to no 
greater than ~0.2 (Figure 3b; Supplementary Note). These theoretical predictions were 
recently experimentally confirmed by Blokzijl et al. who measured the genetic heterogeneity 
in organs of 13 healthy individuals by sequencing organoid cultures derived from 38 
individual cells42. Using their published mutation data, we found that the mean Jaccard 
similarity coefficient in two cells from the same colon was 0.075, from the same liver was 
0.033 and from the same small intestine was 0.011 (Figure 3b; Supplemental Table 14).
Next, we calculated the Jaccard similarity coefficients of the various pairs of metastases on 
the basis of their validated mutations. The coefficients averaged 0.89 (Figure 3b and Table 
1). The Jaccard similarity coefficients of any metastatic lesion relative to any other 
metastatic lesion from the same patient was far higher (minimum of 0.67) than that of any 
modeled normal tissue. Thus, these data demonstrate that the founder cells that seeded these 
metastatic lesions are more highly related than expected from any two randomly chosen 
cells from a single normal tissue (p<0.0003, Welch’s t-test). This finding remained valid 
when using the stringently filtered whole genome data set or when excluding Founder 
mutations (p<0.0027, Welch’s t-test; Figure 3c, Supplemental Tables 13 and 16).
Pairwise genetic distances40 – defined as the total number of non-shared genetic mutations 
within the entire exome among two cells - was also calculated in the metatsases based on 
their validated mutations. We found a maximum of 44, 10, 13, and 36 mutations in Pam01, 
Pam02, Pam03, and Pam04, respectively (Supplemental Tables 15 and 17, Methods). All 
measured distances were significantly lower than expected for two randomly chosen cells 
from a dividing normal tissue (Scenario 2).
Finally, to determine if our findings could be generalized to other patients, we performed 
150× whole exome sequencing of 10 primary and metastatic samples from two additional 
untreated patients that were accrued during the course of this work (Supplementary Figure 9, 
Supplemental Table 18). We again found that the vast majority of variants were shared 
among all samples. Critically, there was complete uniformity of driver gene alterations at the 
single nucleotide in all spatially distinct primary tumor samples and metastases of each 
patient. The average of the Jaccard similarity coefficients was 0.73, again indicating a high 
level of genetic similarity of both driver and passenger genes among the founder cells of the 
metastases.
Phylogenetic analyses of metastases and primary tumor sections
To determine whether the high similarity among metastasis founder cells was consistent with 
the evolution of these tumors, we first performed targeted sequencing on a total of 59 
spatially distinct regions of the four primary tumors from which the metastases emerged 
(Supplemental Table 2). Because the high similarity coefficients of metastases complicated 
evolutionary reconstructions, we used Treeomics43 to derive phylogenetic trees (Figure 4a, 
4b, Supplementary Figures 10–14). Details of this approach are provided in the Methods. In 
general, the trees were consistent with the expected generation of metastases from primary 
tumors. In patients Pam02 and Pam03, we found that metastases within the liver were more 
likely to be derived from different subclones in the primary tumor than from each other 
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(Figure 4a, 4b and Supplementary Figure 10). This suggested that there were a variety of 
subclones in the primary tumor that independently gave rise to highly related, but 
independent metastatic lesions; no single subclone within the primary tumors gave rise to 
all, or even most of, the metastases (Figure 4a, 4b and Supplementary Figures 10a, 10b, 11a, 
and 11b). Notably, all of the driver genes identified in the metastases were also identified in 
all regions of the primary tumors. Phylogenetic analysis also showed that there were no 
definable geographic regions, based on multiregion sampling and mapping prior to 
sequencing, among the subclones in the primary tumor nor could their geographic locations 
be predicted based on their relatedness44 (Figure 4c, 4d, Supplementary Figures 10c, 10d, 
11c, and 11d). For example, in the tumors in which the entire phylogeography could be 
mapped, sections geographically adjacent to each other were observed to be genetically 
distant (e.g. PT7 and PT14 in Figure 4d). Conversely, tumor sections that were 
geographically separated by several centimeters were often more genetically similar (e.g. 
PT2 and PT3 in Figure 4d). These observations can be explained by differential rates of 
clonal expansion or clonal migration, among other possibilities44,45. We note that the high 
genetic similarity with no or only a few detected differences between some samples 
prevented conclusive statements about their evolutionary relationship (indicated by low 
bootstrapping values in Supplementary Figure 11). We found no evidence to support cross-
seeding of metastatic lesions by one another, as expected from a recent study of murine 
pancreatic cancers46.
DISCUSSION
In sum, our data show that the driver gene mutations in the metastases of individual PDAC 
patients are remarkably uniform. This observation is encouraging with respect to the 
potential to treat advanced cancer patients with therapeutic agents targeted to these 
mutations. Whether such uniformity among driver gene mutations in different lesions is 
found in other tumor types in general is not yet known because, as noted in the Introduction, 
so few metastases from untreated patients with other cancer types have been analyzed at a 
genome-wide level. However, available evidence indicates that this uniformity is observed in 
endometrial47, prostate9 and lung cancers6, but perhaps not in kidney cancers.4,48
One caveat of our study is that we did not assess potential Type 3 heterogeneity of 
epigenetic changes among metastases49. Another potential limitation is that the effects of 
copy number variations (CNVs) on genetic drivers in PDAC is difficult to determine, even 
following careful dissection, because of the substantial amounts of non-neoplastic cells that 
remain in the purified DNA. To partially circumvent this challenge, we used 
immunohistochemical methods to evaluate metastatic lesions for inactivation of the most 
commonly altered tumor suppressor genes (Supplementary Figure 2). We were thus able to 
evaluate the effects of epigenetic silencing and certain types of CNV in these genes. We 
indeed identified alterations of these genes, and as with the sequencing data, there was 
complete uniformity among the patterns observed in the metastatic lesions of any individual 
patient. A third limitation is that we only could evaluate known driver genes, identified 
through previous genome-wide studies of more than 500 PDACs. It is possible that 
additional driver genes, not yet discovered, could exhibit Type 3 heterogeneity in the tumors 
we examined. Similarly, it is currently not possible to reliably assign responsibility to 
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specific driver genes in regions of copy number or loss that extend over large regions of 
chromosomes23,24. Heterogeneity of putative, or as yet undiscovered genes or combinations 
of genes in these regions, would not be evident in our analysis.
The absence of Type 3 heterogeneity among PDAC driver gene mutations contrasts with the 
extent of Type 3 heterogeneity within passenger genes in the same tumors. Indeed, we 
observed many genetic differences among the various metastases from the same patient. 
Such heterogeneity is consistent with a large number of other studies, beginning decades 
ago, that demonstrate genetic heterogeneity among tumor cells. The older, classic studies 
focused on karyotypic changes, as no driver gene mutations were known and the technology 
to detect them had not yet been invented. Two recent papers published during the review of 
this paper found that the growth dynamics after clonal expansions of some cancers are 
dominated by neutral evolution, resulting in considerable intratumoral heterogeneity of 
passenger mutations50,51. Our null model builds on these findings and represents a new way 
to contextualize intratumoral heterogeneity in a meaningful fashion. Moreover, our 
mathematical framework can also be used to interpret the genetic heterogeneity in other 
tissues sequenced in the future and thereby help to understand their clonal architecture.
The comparisons between the Jaccard similarity coefficients among metastases and those 
expected and measured in normal tissues, and the phylogenetic evaluations of a large 
number of spatially distinct lesions within the primary tumors, lead to additional insights 
into PDAC tumor evolution. Collectively, they suggest that metastasis is the direct result of 
at least one major selective sweep that affects the majority of cells within the primary tumor 
and includes the final genetic event(s) required for these cells to establish distant, lethal 
lesions.
Materials and Methods
Selection of patient autopsies
The four patients and their respective tissues originated from the Gastrointestinal Cancer 
Rapid Medical Donation program, a collection of over 150 autopsy cases. Informed consent 
was obtained from all subjects. This program has been described previously and was deemed 
in accordance with the Health Insurance Portability and Accountability Act and approved by 
the Johns Hopkins institutional review board26.
Processing of tissue samples
Once the body cavity was opened using standard autopsy techniques, the entire pancreas and 
primary tumor were removed along with each grossly identified metastasis. All tissues were 
immediately flash-frozen in liquid nitrogen and stored at −80°C. Each primary tumor was 
serially sliced into 0.5 cm thick slices followed by sectioning of each slice into 1×1 cm 
tissue samples as described previously. One half of each tissue sample was fixed in 10% 
buffered-formalin while the remaining tissue was preserved at −80°C. Each metastasis was 
macrodissected to remove surrounding non-neoplastic tissue. Each frozen primary tumor 
sample was embedded and frozen in Tissue-Tek OCT for sectioning using a Leica Cryostat. 
For each tissue sample, a 5 μm thick section was taken to create a hematoxylin and eosin 
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slide to visualize neoplastic cellularity using a microscope. A different set of lesions from 
patient Pam01 were evaluated in Ref. 11; the three other patients described in this paper had 
not been evaluated previously. We estimated that the neoplastic cellularity was >50% for 
Pam01, Pam02, and Pam03 and >20% for Pam04.
DNA extraction and quantification
Genomic DNA (gDNA) was extracted from each tissue piece using a standard phenol and 
chloroform extraction followed by precipitation in ethanol. The gDNA was quantified by 
LINE assay (i.e. counting long interspersed elements (LINE) using real-time PCR), a 
particularly sensitive method for calculating gDNA concentration for whole genome 
sequencing. The LINE primers are in Supplemental Table 19. The real-time PCR protocol 
was 50°C for 2 min, 95°C for 2 min, 40 cycles of 94°C for 10 s, 58°C for 15 s, and 70°C for 
30 s, 95°C for 15 s, and 60°C for 30 s. The PCR reactions were carried out using Platinum 
SYBR Green qPCR mastermix (Invitrogen). Only those tissue samples that were confirmed 
to be of high quality and suitable concentration (>25 ng/μl of amplifiable gDNA) were used 
for WGS or WES.
Whole genome sequencing and alignment
For whole genome sequencing (WGS), several metastases were chosen from all four cases 
along with three geographically distinct sections of the primary tumor from three of the four 
cases for a total of 35 samples. WGS was performed on an Illumina Hi-Seq 2000 platform 
for a target coverage of 60×. Following the completion of sequencing, the data were 
retrieved and analyzed in silico to determine overall coverage and read quality. Reads were 
aligned to the hg19 human reference genome. All low-quality, poorly aligned, or dbSNP 
containing reads were removed from further analysis.
To identify potential drivers, we queried the variant lists for mutations through a 
combination of previously identified oncogenes and tumor suppressors. This included driver 
genes identified via a ratiometric approach16, documented hotspots28, and significantly 
mutated genes identified in recent sequencing studies of pancreatic cancer36,52,37,27,28. For a 
variant to be considered, it had to be non-silent and occur within two or more of the 
following types of genes: 1) an oncogene or tumor suppressor gene16, 2) a significantly 
mutated or known driver gene/pathway in PDAC21,27,36,37,52, 3) a key gene or pathway in 
PDAC21, or 4) a gene known to have bona fide hotspots28 (Supplemental Table 12).
Whole exome sequencing, alignment, and filtering
The data processing pipeline for detecting variants in Illumina HiSeq data was as follows. 
First the FASTQ files were processed to remove any adapter sequences at the end of the 
reads using cutadapt (v1.6). The files were then mapped using the BWA mapper (bwa mem 
v0.7.12). After mapping the SAM files were sorted and read group tags were added using 
the PICARD tools. After sorting in coordinate order the BAMs were processed with 
PICARD MarkDuplicates. The marked BAM files were then processed using the GATK 
toolkit (v 3.2) according the best practices for tumor-normal pairs. They were first realigned 
using the InDel realigner and then the base quality values were recalibrated with the 
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BaseQRecalibrator. Somatic variants are then called in the processed BAMs using muTect 
(v1.1.7).
To identify somatic variants for tumor samples from Pam13 and Pam16, the criteria we used 
were as follows. Each variant must have been observed in ≥ 3 reads; each mutant must have 
been observed in at least one read in both directions (i.e., 5′ to 3′ and 3′ to 5′ relative to 
reference genome); each mutant must not have been observed in >2% of the reads of the 
matched normal sample; the minimum mutant allele frequency of 5%; the matched normal 
must have had at least 10 reads total. With manual inspection of the raw data, this approach 
resulted in a total of 330 putative mutations for phylogenetic analysis. Driver gene mutations 
were analyzed using the same approach from the WGS data (Supplemental Table 18).
Filtering of whole genome sequencing data and visualization
Whole genome sequencing generated a large list of potential mutations, even after 
conventional filtering based on quality scores. A total of 54,433 discrete coding and 
noncoding somatic mutations were identified with an average of 4,759 mutations per 
sample. We assessed these data with the goal of identifying bona fide mutations and 
eliminating sequence artifacts. The criteria used to achieve this goal were relaxed compared 
to what we have previously used16,53 given the variation in neoplastic cell content among the 
samples (Supplemental Table 3) and our desire to identify somatic mutations (i.e., high 
sensitivity, intermediate specificity). Furthermore, we planned on experimentally validating 
each mutation and could thereby tolerate a higher fraction of false positives in this analysis. 
The criteria we used were as follows. Each mutant must have been observed in > 3 reads 
(read defined as the output from one cluster on the Illumina instrument); each mutant must 
have been observed in at least one read in both directions (i.e., 5′ to 3′ and 3′ to 5′ relative 
to reference genome); each mutant must not have been observed in any reads of the matched 
normal sample; minimum mutant allele frequency of 10% in samples from patients Pam01, 
Pam02, & Pam03 and 5% in samples from patient Pam04 given the lower neoplastic cell 
content of the samples from patient Pam04 (Supplemental Table 3). This analysis yielded a 
total of 3,811 potential mutations for subsequent validation.
Targeted sequencing design and validation
Strict filtering of the WGS data resulted in a highly conservative and confident list of 
potential mutations that defined the clonal mutation profile for each tumor sample. This list 
of 3811 variants was used to design a targeted sequencing effort that incorporated the 
mutation position +/− 50 base pairs in either direction. Additionally, we aimed to increase 
our sensitivity of mutation detection by increasing our target coverage to >200×. To do this, 
we implemented an Illumina chip-based targeted sequencing approach. Once sequencing 
was completed, the raw data were aligned and processed as described for the WGS data. To 
filter the chip data for high quality mutations, we removed those that had greater than 2% 
mutant allele fraction, no distinct coverage in the corresponding normal sample, and did not 
pass manual review in the WGS raw data.
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Evolutionary analysis methods
We leveraged the passenger mutations identified in the WGS of each sample to inferred an 
overall false positive rate for the mutations of 0.23%, given that two independent cancers 
were extremely unlikely to harbor identical passenger mutations. In detail, we counted the 
number of reads in the targeted sequencing data reporting a passenger mutation in samples 
of different patients than where the mutation was originally identified in the WGS data. The 
counted number of reads divided by the total number of reads at these positions were used to 
estimate the false-positive rate. We then used a statistical approach, based on mutant read 
counts and overall coverage of the targeted sequencing data, to determine whether a variant 
was present, absent, or unknown in each matched sample by calculating a p-value for each 
variant via a binomial distribution. The null hypothesis was that the mutation was absent. We 
used the step-up method of Benjamini and Hochberg54 to control for an average false 
discovery rate (FDR) of 5% in the combined set of p-values from all samples in a patient. 
Variants with a rejected null hypothesis were labeled as present. The remaining variants 
(failed to reject the null hypothesis) were labeled as absent if their coverage was ≥100× and 
otherwise labeled as unknown. Variants determined to be present or absent were then used 
for phylogenetic analysis. However, we excluded tumor samples with a median coverage 
<100× or a median all-mutant allele fraction of <5% based on targeted sequencing data.
Based on the validation and filtering of the variants above that underwent targeted re-
sequencing, we derived phylogenies for each patient. The evolutionary trees were “rooted” 
at the matched patient’s normal sample and the leaves were formed by the tumor samples 
(i.e. distinct parts of primary tumors or distinct metastatic lesions). We applied Treeomics, a 
new tool to reconstruct the phylogeny of a cancer with commonly available sequencing 
technologies43. Treeomics employs a uniquely-designed Bayesian inference model to 
account for error-prone sequencing and varying low neoplastic cell content to calculate the 
probability that a specific variant is present or absent in each sequenced lesion. Based on 
Mixed Integer Linear Programming, we obtained phylogenies consistent with the biological 
processes underlying cancer evolution55–57. In the case of many samples (>12) per patient, 
we used a heuristic to efficiently explore the solution space and therefore the acquisition of 
some variants remained ambiguous. For consistency we assumed a sequencing error rate of 
0.5% across all subjects in the phylogenetic analysis.
We found that the large majority of mutations was acquired prior to genetic divergence in 
our samples. The low extent of genetic heterogeneity among the samples resulted in 
relatively “low” support (indicated by rather low bootstrapping values) for branching events, 
a difficulty also observed in sequencing studies of incipient or recently diverged species. 
Across the four patients, the number of acquired mutations ranged from 92–219. Since we 
obtained ~50 samples per subject, it seems unlikely that biologically relevant tumor 
subclones would fail to be detected in all samples of a given patient. However, we cannot 
completely exclude this possibility.
Evolutionary analysis results
The inferred phylogenetic tree of Pam01 indicates that the pelvic lymph node metastasis 1 
(NoM1) was apparently seeded significantly earlier than portal lymph node metastasis 
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(NoM2) and the liver metastasis (LiM1) (Supplementary Figure 1a and 12). The portal 
lymph node metastasis and the liver metastasis originate from a genetically similar subclone 
(Supplementary Figure 12).
For Pam02, we found that many of the liver metastases were more closely related to one of 
the primary tumor sections than they were to each other (Supplementary Figure 1b). This 
provided strong evidence that coexistent metastases within the liver were more likely to be 
derived from different subclones (or regions) in the primary tumor than from each other 
(Figure 4). Interestingly, we also noted that these regions were not obviously related to 
adjacent regions, and were often more related to distant subclones within the primary tumor 
(Figure 4d).
In Pam03, we evaluated four additional metastases (LiM6–9) to assist our phylogenetic 
analysis. Our inferred phylogenetic tree showed that the two liver metastases (LiM2 and 4) 
were closely related (Supplementary Figure 1c, and 10). The analyses also indicate that the 
lung metastasis diverged earlier in the evolution of this tumor than the liver metastases 
(Supplementary Figure 10).
For Pam04, the low neoplastic cell content hindered the derivation of robust phylogenies 
(Supplementary Figure 11). Interestingly, the primary tumor for this case demonstrated a 
similar mixed pattern without evidence for strictly spatially distinct subclones 
(Supplementary Figure 11). It was notable that this patient was the only one with a 
peritoneal pattern of metastasis, a form of metastasis unrelated to hematogenous spread58. 
Exchange of cells within the peritoneum could in theory explain the difficult tree 
reconstructions.
We also inferred phylogenies for the two patients for which we had whole exome 
sequencing. For Pam13 (Supplementary Figure 13), two liver mets (LiM1 and LiM3) 
evolved from the same subclone. The third liver met (LiM2) was inferred to be more closely 
related to the primary tumor (PT1) than to the other two liver mets. For Pam16 
(Supplementary Figure 14), the lymph node and liver met more closely relate to one primary 
tumor section (PT2) than the other (PT1).
Immunohistochemistry for driver gene expression
Although we restricted our evolutionary analyses to point mutations, we sought to determine 
the extent to which alternative genetic events may be affecting common PDAC drivers. 
Briefly, slides bearing tissue were heated at 60°C for 10 minutes, deparaffinized, and 
rehydrated using a ethanol gradient to water. Slides were exposed to DAKO Target Retrieval 
solution for 25 minutes in steam conditions and allowed to cool for 30 minutes. Tissue slides 
were subsequently washed. Each antibody was diluted as per manufacturer protocol in 
DAKO antibody diluent. Slides were treated with antibody dilution for one hour at room 
temperature and subsequently washed. DAKO Labeled Polymer HRP was used as a 
secondary antibody exposed to slides for 10 minutes followed by slide washing. Each slide 
was treated with DAB for 2.5 minutes, washed in deionized water, then stained with 
Hematoxylin and washed. Any other antibody specific procedures were implemented as 
needed. Tissue slides were subsequently dehydrated through an increasing gradient of 
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ethanol, dried, and visualized. We implemented immunohistochemistry for CDKN2A 
(Ventana 725-4713), TP53 (Dako M700101-2), SMAD4 (Santa Cruz Biotechnology 
sc-7966), and ARID1A (Santa Cruz Biotechnology sc-32761) on matched tumor sections 
from each of the four cases (Supplementary Figure 2). In all examples the expression 
patterns of each driver (whether abnormal or not) remained unchanged among the primary 
tumor subclones and metastases within each case and do not change our conclusions or 
interpretations of the genetic data for each patient (Supplementary Figure 2). We also used 
this approach to determine the expression patterns in the primary tumor and metastasis 
samples for Pam01. The presence of nuclear labeling observed for both SMAD4 and 
ARID1A are consistent across all samples, indicating that these genes were not affected by 
copy number alterations (i.e. homozygous deletions) that may have been missed by our 
method (Figure 2b).
The expression patterns among all samples from individual patients were identical, 
consistent with previous results59. The expression patterns of the driver genes were also 
concordant with expectations from the sequencing data. For CDKN2A, we observed a loss 
of expression in all four patients among all tumor cells: this is an example of a driver gene 
with no point mutations detected by sequencing but with loss of expression, indicating either 
methylation or a homozygous deletion. For TP53, Pam02 demonstrated p53 at stabilized, 
high nuclear levels as expected from the p. L344P missense mutation identified by WGS. By 
contrast Pam01 and Pam03 showed loss of p53 expression in the cancer cells (internal 
control normal cells were positive) despite not finding a mutation by sequencing, also 
indicating a homozygous deletion in these two tumors. This is consistent with our prior 
observation of a homozygous deletion of exons 1–3 in Pam01, (known as Pa04C in that 
study)36. Pam04 p53 expression patterns showed weak positive labeling of tumor nuclei, and 
no mutation was identified by sequencing, consistent with the presence of a wild type TP53 
gene. Interestingly, SMAD4 expression was retained in Pam01, Pam02, and Pam03, 
consistent with the fact that SMAD4 loss is not a requirement for metastasis formation in 
pancreatic cancer. Pam04, the only tumor with a SMAD4 p.D351G missense mutation 
detected by sequencing, showed scattered positive nuclear labeling. This expression pattern 
is consistent with prior observations of retention of low levels of mutant nuclear SMAD4 
protein expression when the missense mutation is located in the mutation cluster region of 
the gene (codons 330–370 within the MH2 domain)60. For ARID1A, a p.Y579X nonsense 
mutation was identified in Pam02 and immunolabeling for the ARID1A gene project 
indicated loss of protein expression. Arid1A expression was retained in Pam01, Pam02 and 
Pam03 that were wild type per sequencing.
Analyses of SCNAs and B-allele frequencies
For tumors that underwent whole genome sequencing, we used Control-FREEC package to 
call CNVs. All read counts in BAM files of tumor samples were first corrected for read 
counts in the matched normal BAM file and then normalized for GC-content bias given the 
hg19 reference genome61. Ploidy was assumed 2 for all cases. Contamination ratio by 
normal cells estimated by targeted resequencing was also provided for each individual tumor 
sample. Window and step sizes were set 50000 and 10000, respectively. Threshold for 
segmentation of normalized profiles was set 0.6 that is lower than default in order to get 
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more predicted CNV segments. We finally selected significant CNVs that have passed both 
Wilcoxon and Kolmogorov-Smirnov test (p-values <0.05)61,62.
Additionally, more than 3000 SNPs were used to estimate B-allele frequencies at the 
chromosomal level in two cases, Pam01 and Pam02. Major copy number alterations and loss 
of heterozygosity events were observable in all primary tumor sections and metastases 
(Supplementary Figures 2–5).
To identify putative driver genes involved in SCNAs (Supplemental Table 7), the SCNA had 
to be an amplification with a CN = ≥5 or a deletion with a CN = 0 in at least one tumor 
sample within each case, involving 1) an oncogene or tumor suppressor gene16, or 2) a key 
gene or pathway in PDAC21. For identifying recurrent chromosomal losses or gains, at least 
one SCNA had to be an amplification with a CN = ≥5 or a deletion with a CN = 0 in at least 
one tumor sample within each case while occurring in a recurrently altered chromosome 
band in PDAC27.
Structural variant analysis
To identify structural variants in the WGS data, the GROUPER module in CASAVA (version 
1.1a1) was used with standard settings. Structural variants present in the patient-matched 
normal were filtered from subsequent analysis. Driver genes were identified using the same 
references as the SCNAs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Distributions of metastatic disease of four pancreatic cancer patients
a. Anatomic locations of the primary carcinomas (Pam02–Pam04) and discrete metastases 
(all cases) used for whole genome sequencing. b. Histology of three geographically-
independent primary tumor samples from patient Pam03 used for sequencing. c. Low and 
high power view of a discrete liver metastasis from patient Pam03. The dashed line in the 
low power view outlines the borders of the metastasis that measured 1.5 cm in diameter. 
scale bars, 100 μm.
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Figure 2. Features of Phylogenies and Driver Genes in Pam01, Pam02, Pam03, and Pam04
a. Time is represented on the vertical axis, divergence is represented on the horizontal axis. 
Trunks are colored blue, while branches leading to primary tumors are orange and 
metastases are green. Each tree is rooted at the germline (“g”). Branch and trunk lengths are 
relative to the number of underlying variants. Driver alterations are labeled where each is 
inferred to occur during tumor evolution. b. Representative immunolabeling for CDKN2A, 
TP53, and SMAD4 illustrating the concordance of labeling for each sample analyzed by 
WGS for Pam01 in the matched available formalin-fixed paraffin embedded tumor tissues 
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for the primary tumor (PT5) and metastases LiM1, LiM2, NoM1 and NoM2. scale bars, 10 
μm. c. CIRCOS plots showing statistically significant copy number variants among Pam01 
whole genome samples. For each sample ring, the y-axis spans −2 to 2, with 0 representing a 
normal diploid copy number in unaffected regions, deletions as a −1 or −2, and 
amplifications as 1 or 2. Copy number variants > 2 are scored as 2. All values were log 2 
transformed for visualization. The outermost ring shows the chromosomes in a clock-wise 
order. Deletions are shown in blue while amplifications are red. Gene names are those 
described in Supplemental Table 7. From innermost to outermost the samples are PT5, 
LiM1, LiM2, NoM1 and NoM2.
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Figure 3. Somatic evolution of normal tissues
a. Three hypothetical scenarios for normal tissue somatic evolution are considered, T (far 
right) indicates time. In (1) the organ follows a pure birth process for development with no 
further cell division. In (2), the organ follows a pure birth process for development of stem 
cells, each founding a single crypt and dividing over time. The organ in (3) follows the same 
development as (2) but with substantial mixing and replacement of stem cells. b. The 
expected Jaccard similarity coefficient, with 0 for no identical mutations and 1 for complete 
genetic identity among any two cell lineages. The coefficient ranges for normal tissues and 
metastases are shown in green and red, respectively. The similarity coefficient among the 
stem-cell-like cells (orange cells in (1); green cells in (2) and (3)) was always below 0.2 in 
all three scenarios for relevant parameter values. Accounting for possibly additional 
mutations in short-lived terminally differentiated cells would further increase the 
heterogeneity within an organ. c. Scatterplot demonstrating that the three types of normal 
tissue estimates have significantly lower Jaccard similarity coefficients (p=0.0027).
Makohon-Moore et al. Page 22
Nat Genet. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. Inferred phylogeny and three dimensional geography of primary tumor sections and 
metastases for patient Pam02
Phylogeny was inferred by Treeomics43. See Supplemental Table 3 for sample identity. a. 
Time is represented on the left axis, divergence is represented on the horizontal axis. Colors 
indicate discrete tumor samples and follow the rainbow spectrum, scaling from ancestral to 
descendant as indicated by the evolutionary relationships. b. Phylogenetic tree relative to 
time and number of acquired mutations. Primary tumors are labeled at “PT” followed by 
sequential numbers, the remaining samples are liver mets labeled as LiM and also followed 
by a sequential number. Hypothetical subclones are indicated by “SC” followed by the 
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subclone number and enclosed by a dashed outline. The numbers of acquired mutations are 
in blue font with a “+” sign. Percentages denote bootstrapping values. c. The three 
dimensional size of the original primary tumor in centimeters. d. Primary tumor slices are 
numbered according to the original sectioning and plane order.
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